KOD

Kodiak Sciences (KOD)

Kodiak Sciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:KOD

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/03	05 : 30	PR Newswire (US)	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform	NASDAQ:KOD	Kodiak Sciences Inc
2024/03/28	19 : 30	PR Newswire (US)	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:KOD	Kodiak Sciences Inc
2024/03/26	19 : 15	PR Newswire (US)	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024	NASDAQ:KOD	Kodiak Sciences Inc
2024/02/15	06 : 23	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:KOD	Kodiak Sciences Inc
2024/01/30	20 : 30	PR Newswire (US)	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting	NASDAQ:KOD	Kodiak Sciences Inc
2024/01/05	06 : 15	PR Newswire (US)	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:KOD	Kodiak Sciences Inc
2023/11/22	06 : 15	PR Newswire (US)	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:KOD	Kodiak Sciences Inc
2023/11/15	06 : 01	PR Newswire (US)	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:KOD	Kodiak Sciences Inc
2023/11/06	20 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KOD	Kodiak Sciences Inc
2023/11/06	19 : 00	PR Newswire (US)	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission	NASDAQ:KOD	Kodiak Sciences Inc
2023/11/02	12 : 21	PR Newswire (US)	KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING	NASDAQ:KOD	Kodiak Sciences Inc
2023/10/11	19 : 00	PR Newswire (US)	Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society	NASDAQ:KOD	Kodiak Sciences Inc
2023/09/08	19 : 00	PR Newswire (US)	Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:KOD	Kodiak Sciences Inc
2023/09/07	19 : 00	PR Newswire (US)	New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion	NASDAQ:KOD	Kodiak Sciences Inc
2023/08/18	06 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KOD	Kodiak Sciences Inc
2023/08/15	05 : 33	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:KOD	Kodiak Sciences Inc
2023/08/15	05 : 12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KOD	Kodiak Sciences Inc
2023/08/15	05 : 01	PR Newswire (US)	Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:KOD	Kodiak Sciences Inc
2023/07/24	19 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:KOD	Kodiak Sciences Inc
2023/07/24	19 : 00	PR Newswire (US)	Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program	NASDAQ:KOD	Kodiak Sciences Inc
2023/07/04	05 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KOD	Kodiak Sciences Inc
2023/07/04	05 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/28	06 : 36	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/28	06 : 33	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/28	06 : 32	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/14	06 : 34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/14	06 : 31	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/08	05 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:KOD	Kodiak Sciences Inc
2023/06/05	19 : 07	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:KOD	Kodiak Sciences Inc
2023/05/31	05 : 15	PR Newswire (US)	Kodiak Sciences to Present at Upcoming Investor Conferences	NASDAQ:KOD	Kodiak Sciences Inc